HIMSSCast
How COVID-19 has accelerated healthcare trends, with MoneyBall Medicine’s Harry Glorikian
See Original Post Here: HIMSSCast
In Harry Glorikian’s MoneyBall Medicine, he writes about various interconnected trends that have been shaping healthcare for the past few years: value-based care, precision medicine, cost transparency, digital health, and big data. Some of those trends have been accelerated by recent seismic shifts in healthcare. Others could still be slowed down by regulatory and reimbursement barriers.
In today’s episode, Glorikian joins host Jonah Comstock for a wide-ranging discussion of healthcare’s future.
About Harry Glorikian
Harry Glorikian is an influential global business expert with more than three decades of experience building successful ventures in North America, Europe, Asia and the rest of the world. Harry is well known for achievements in life sciences, healthcare, diagnostics, healthcare IT and the convergence of these areas. He is a sought-after speaker, frequently quoted in the media, and regularly asked to assess, influence, and be part of innovative concepts and trends.
He is currently a General Partner at New Ventures Funds (NV). Before joining NV Funds, he served as an Entrepreneur In Residence to GE Ventures – New Business Creation Group. He currently serves on the board of GeneNews Ltd. He also serves on the advisory board of Evidation Health (a digital health startup launched with support from GE Ventures), and several other companies. He is also a co-founder and an advisory board member of DrawBridge Health (a revolutionary diagnostics startup launched with support from GE Ventures).
Harry holds an MBA from Boston University and a bachelor’s degree from San Francisco State University. Harry has addressed the NIH, Molecular Medicine Tri-Conference, World Theranostics Congress and other audiences, worldwide. He has authored numerous articles, appeared on CBS Evening News and been quoted regularly by Dow Jones, The Boston Globe, Los Angeles Times, London Independent, Medical Device Daily, Science Magazine, Genetic Engineering News and many others.
